1 RESEARCH ARTICLE

- 2 Title: An Alternative Approach to Tablet Splitting and Grinding for Medication Administration
- 3
- 4 Rajneesh Taneja¹, Joseph Scarim², Poonam G Pande^{1*}, Anthony Scarim², Milap C Nahata³, Rita K
- 5 Jew⁴, Koteswara Inabathina¹
- 6
- ⁷ ¹Global Alliance for TB Drug Development (TB Alliance); ²JSAS Services Inc; ³Institute of
- 8 Therapeutic Innovations and Outcomes, Colleges of Pharmacy and Medicine, The Ohio State
- 9 University; ⁴Institute for Safe Medication Practices (ISMP)
- 10
- 11 *Correspondence
- 12 Poonam Pande, TB Alliance, 40 Wall Street, 24th Floor, New York, NY 10005
- 13 e-mail: poonam.pande-consultant@tballiance.org
- 14
- 15 Running head: Alternative method for suspending oral tablets
- 16

17 Abstract

18	Purpose. Tablet formulations fail to meet the needs of patients unable to swallow tablets such
19	as pediatric, elderly, and patients that must receive medications via feeding tubes. Our aim was
20	to develop and test a new, simple device (XTEMP- R^{TM}) and the methodology for converting
21	tablets into a homogeneous suspension for medication administration.
22	Methods. We developed a new device comprised of a flexible receptacle, a tight-fitting cap, and
23	a suction cup bottom to convert tablets into liquid preparations. TB treatment drugs, TBAJ-876
24	and TBI-223, were dispersed within the device utilizing water and commonly available
25	suspending vehicles. We investigated the effectiveness of the XTEMP-R device in dispersing
26	tablets. This was accomplished by visual observations, determining the fineness of dispersion,
27	and measuring the total drug recovery from the dispersions in XTEMP-R. We investigated the
28	accuracy and reproducibility of delivering aliquots from these suspensions by determining the
29	dose reproducibility upon suspension and upon redispersion after 24 hours. The effectiveness
30	of the device was also evaluated using commercially available tablets of acetaminophen,
31	amlodipine, glimepiride, metformin and valsartan.
32	Results. The suspensions were visually uniform without any large particles. The suspensions
33	passed through #18 sieve confirming that the particles were less than 1000 μ m. Average total
34	dose recovery of three suspensions each was determined to be 101.3% and 99.2% for TBI-223
35	and TBAJ-876, respectively. Reproducibility from aliquots of 2 mL each were 98.9-99.7% for
36	three replicates of TBI-223 suspensions, and 102.6-103.2% for TBAJ-876 suspensions. Aliquots
37	tested after 24 hours confirmed uniform re-dispersibility.

38	Conclusion. We have demonstrated that XTEMP-R can be utilized to prepare homogeneous
39	suspensions can be prepared conveniently and efficiently in less than 10 minutes without any
40	drug loss. Aliquots for partial dose delivery can be withdrawn accurately. These findings
41	demonstrate that XTEMP-R can be used to accurately deliver doses of suspensions for patients
42	who cannot swallow tablets.
43	
44	Keywords: aliquot, device, dosing, dysphagia, geriatric, pediatric, suspension
45	

- 46

47 Introduction

Tablets remain the most common modality for oral dose administration of drugs. They 48 represent 28 of the top 30 prescription drugs in 2021 [1]. However, these formulations are not 49 50 suitable for some patients, especially young children, and those suffering from dysphagia. 51 Tablet administration is also a challenge for patients receiving enteral tube feeding [2]. If an 52 alternate oral formulation or route of administration is unavailable, manipulation of the dosage form may be undertaken at the point of administration to provide the prescribed dose [3]. 53 Manipulation involves physical alteration of the dosage form, including tablet splitting, 54 crushing, or grinding [4]. Dose adjustment is commonly achieved through tablet splitting, 55 whereas tablet crushing or grinding aid the swallowing or administration via an enteral feeding 56 57 tube [4]. 58 Tablets are often pulverized (crushed or ground) with a mortar and pestle or other tablet grinding device to facilitate administration [2,5]. However, this process is tedious and often 59 leads to the loss of the prescribed dose during preparation or administration [5]. In one study, it 60 was demonstrated that two rinses of the grinding devices with water were required to prevent 61 significant drug loss [5]. Screwcap crushers yield larger particles that are not suited for feeding 62 tube administration [4]. Also, some hazardous drugs may pose risks to caregivers preparing the 63 doses through the inhalation of generated powder containing the drug, or through contact with 64 skin, nose, and eyes [4]. 65

Another common practice is tablet splitting [6,7]. It is used for many reasons including
delivering partial dose of the tablet, facilitating swallowing, or cost savings [8,9]. However, this

68	process raises the issues of drug loss, variation in dose uniformity, dose accuracy, and weight
69	uniformity between fragments [8]. Many tablets may not be suitable for splitting due to factors
70	such as hardness, size, shape, or absence of score line.
71	Steadman and colleagues [5] called for a device that minimizes drug loss and maximizes
72	medication delivery, i.e., a device that ensures a sealed environment for crushing followed by
73	mixing with a fluid and subsequent consumption from the same receptacle [5]. Salmon and
74	colleagues [2] expressed a need for a combined crushing and suspending device.
75	TBAJ-876 (US IND number 145,349) and TBI-223 (US IND Number 134,334) are two new
76	chemical entities under development as immediate-release tablets for the treatment of
77	tuberculosis. The tablets are available in 100 mg and 600 mg strengths, respectively. Dose
78	titration is required while conducting early clinical studies with these drugs. A liquid
79	formulation allows for the flexibility of aliquoting the desired dose in any fraction. The
80	alternative is to manufacture tablets in multiple strengths and choose a combination of
81	different strength tablets for the desired dose.
82	The objective of our work was to develop a device and methodology that enabled the
83	dispersion of TBI-223 and TBAJ-876 immediate-release tablets into a suspension in water
84	without the need for crushing or grinding in a contained environment. Further, a suspending
85	vehicle can be added to make it into a homogenous suspension that allows for accurate partial
86	dose delivery.

A new, simple device (XTEMP-R[™]) was developed, and the methodology for converting tablets
into a homogeneous suspension with this device is described in this paper. This device and

- 89 methodology can be used in any setting without crushing, grinding, or splitting the tablet
- 90 dosage form. Flavors and sweeteners may be added to the suspension for enhancing
- 91 palatability. Our work is not suited for modified release, delayed-release, or controlled-release
- 92 tablets and capsules. In this paper, the term tablet refers to immediate-release tablet. The term
- 93 dispersion refers to the disintegration of the tablet in a liquid media resulting in a suspension.
- 94 The terms dispersion and suspension convey the same meaning.
- 95 To demonstrate the utility of the XTEMP-R device, we investigated (a) time to disperse the
- tablets, (b) fineness of dispersion, (c) total dose recovery, and (d) accuracy of delivering aliquots
- 97 from suspensions.
- 98 In addition to TBAJ-876 and TBI-223, the dispersibility of a few commercial tablets was also
- 99 conducted to verify the utility of this device.

100 Materials and methods

101 **Drugs and vehicles**

- 102 TBI-223 IR tablets, 600 mg, TB Alliance, lot 6767AU01, retest 11/2022
- 103 TBAJ-876 Tablets, 100 mg, TB Alliance, Batch 6767BG01, retest 10/2022
- 104 Valsartan tablets, USP, 320 mg (Macleods, lot EVI2032A, exp 07/2022)
- 105 Tylenol[®] (acetaminophen) extra-strength tablets, 500 mg (Johnson & Johnson, lot AFA111, exp
- 106 05/2025)
- 107 Metformin tablets, USP, 1000 mg (Ascend, lot 4200094A, exp 07/2023)
- 108 Glimepiride tablets, USP, 2 mg (Accord, lot P2005847, exp 10/2023)
- 109 Amlodipine tablets, USP, 2.5 mg, (Ascend, lot 21140696, exp 01/2024)
- 110 ORA-Blend[®], Perrigo, lot 2077398, exp. 28 Feb 2025
- 111 ORA-Sweet[®], Perrigo, lot 1346049, exp 31 July 2024
- 112 Water, Distilled, Culligan, R22075 06:56 L1 Best By 03/2023

113

114 Chemicals

- 115 Acetonitrile, HPLC, Spectrum Chemical Mfg. Corp, item HP412, lot 20020323
- 116 Water, HPLC, Concord Technology, 8003LC4000, lot 201222
- 117 Ammonium Acetate, Sigma-Aldrich, item 73594-25G-F, lot BCCH0197
- 118 Trifluoroacetic acid (TFA), HPLC grade, Sigma-Aldrich, item 91707-10X1ML, lot bccg6537
- 119 Sodium lauryl sulfate (SLS), Sigma-Aldrich, Reagent grade, item 436143, lot MKCQ6608

120

121 Equipment and supplies

- 122 HPLC: Hitachi L-2100 pump, Shimadzu SPD-10AVP detector, Shimadzu SCL-10AVP controller,
- 123 Shimadzu CTO-AVP column heater, SRI Instruments PeakSimple chromatography data system
- 124 Column: Zorbax Bonus RP (C18, 4.6 mm x 150 mm, 3.5μm)
- 125 Column: Waters Symmetry Shield RP-8 (4.6 mm x 150 mm, 5μm)
- 126 Syringe Filters, Tisch Scientific, Glass Fiber, Hydrophilic, 25mm, 1.0um, PN SF14699, lot
- 127 170420083
- 128 Syringe Filters, PALL Life Sciences, PVDF, 13mm, 0.45um, PN 4545, lot A10648946
- 129

130 **XTEMP-RTM device**

- 131 XTEMP-R comprises a flexible receptacle, a tight-fitting cap, and a suction cup bottom (Fig 1). It
- is a soft walled device manufactured with biocompatible, low hardness HCR (high-consistency
- 133 silicone rubber) sourced from Wacker, Germany. The construction material, platinum-cured
- silicone, complies with FDA 21 CFR 177.2600, German Bfr XV, France Arrete Du 25, ROHS,
- 135 TSE/BSE free, USP Class VI Certification, and ISO 10993 Certification. These devices are
- produced by a compression molding process (Ami Polymers Pvt. Ltd., India) in a class 10000
- 137 cleanroom. The height of the XTEMP-R device is 140 mm, the internal diameter is 22 mm, and
- the capacity is approximately 40 mL. The device has volume markings on the outside at 5-mL

139	intervals starting at 15 mL	. This device is resista	nt to extremes of	environments and
-----	-----------------------------	--------------------------	-------------------	------------------

- 140 temperatures and is designed to be leak-resistant and is easy to squeeze between the fingers
- 141 for manual dispersion of the tablets.
- 142 **Fig 1. X-TEMP-R[™] Device.**
- 143

144 Preparation of suspensions from tablets using XTEMP-R

- 145 The general preparation technique is displayed in Fig 2 with preparation of TBI-223 suspension
- as an example.
- 147 Fig 2. Preparation of TBI-223 Suspension from Tablets.
- 148

149 **TBAJ-876**

150 One tablet of TBAJ-876 100 mg was added to the XTEMP-R followed by 5 mL of water. The

device was capped and swirled for 5 seconds and left undisturbed for 5 minutes. Then the

tablet was manually massaged in the XTEMP-R for 2 minutes. ORA-Sweet suspending vehicle,

153 19.5 mL was added to the dispersion in the XTEMP-R make a final volume that coincided with

- the 25-mL mark on the device and a final concentration of 4 mg/mL. The device was capped
- and shaken 25 times to mix thoroughly. For redispersion, the suspension was shaken 25 times.

156 **TBI-223**

One tablet of TBI-223 600 mg was added to the XTEMP-R followed by 5 mL of water. The device was capped and swirled for 5 seconds and left undisturbed for 5 minutes. Then the tablet was manually massaged in the XTEMP-R for 2 minutes. ORA-Blend suspending vehicle, 9.4 mL was added to the dispersion in the XTEMP-R to make a final volume that coincided with the 15-mL

- 161 mark on the device and a final concentration of 40 mg/mL. The device was capped and shaken
- 162 25 times to mix thoroughly. For redispersion, the suspension was shaken 25 times.

163 **Evaluation of suspensions prepared in XTEMP-R**

164 Visual observation

165 **TBAJ-876 and TBI-223**

- 166 The prepared suspensions of TBAJ-876 and of TBI-223 were shaken, and then an aliquot of each
- 167 was poured onto a watch glass. The suspensions were examined for color, uniformity, and
- 168 presence of large particles, agglomerates, or clumps.

169 **Fineness of dispersion**

- 170 Dispersions of tablets in water prepared in the XTEMP-R device were tested for fineness of
- 171 dispersion.

172 TBAJ-876 and TBI-223

- 173 One tablet was added to the XTEMP-R followed by 5 mL of water. The tablet was allowed to
- soak for 5 minutes, followed by 2 minutes of massaging in the XTEMP-R. The dispersion was
- poured through a #18 sieve (1000 μ m opening) with a pan at the bottom for collecting the
- dispersion. This test was performed in triplicate by each of two analysts.

177 Total dose recovery from tablet dispersion in XTEMP-R

178 **TBAJ-876**

- 179 The prepared 25 mL suspension in the XTEMP-R device was shaken 25 times and transferred to
- 180 a 250 mL volumetric flask. The device was rinsed with 15 mL of water and the rinse was added
- to the volumetric flask with the suspension. This stock solution was diluted to volume with 1:1
- acetonitrile:water. A sample of this stock solution was further diluted with diluent (Table 1) to a

183	concentration of 0.04 mg/mL. An aliquot of this diluted sample was filtered and analyzed by
184	HPLC as described under Analytical test methods below. The recovery was tested on three
185	preparations.
186	TBI-223
187	The prepared 15 mL suspension in the XTEMP-R device was shaken 25 times and transferred to
188	a 250 mL volumetric flask. The device was rinsed with 15 mL of water and the rinse was added
189	to the volumetric flask with the suspension. A volume of 30 mL of acetonitrile was added to the
190	flask and mixed. This stock solution was diluted with diluent (Table 1) to volume. A sample of
191	this stock was further diluted with diluent to a concentration of 0.05 mg/mL. An aliquot of this
192	sample was filtered and analyzed by HPLC as described under Analytical test methods below.
193	The recovery was tested on three preparations.
194	Dose reproducibility of aliquots of tablet dispersion in XTEMP-R
194 195	Dose reproducibility of aliquots of tablet dispersion in XTEMP-R A general technique for withdrawal of aliquots for partial doses is represented in Fig 3.
195	A general technique for withdrawal of aliquots for partial doses is represented in Fig 3.
195 196	A general technique for withdrawal of aliquots for partial doses is represented in Fig 3.
195 196 197	A general technique for withdrawal of aliquots for partial doses is represented in Fig 3. Fig 3. Withdrawal of an Aliquot from XTEMP-R for Partial Dose of TBI-223 Suspension.
195 196 197 198	A general technique for withdrawal of aliquots for partial doses is represented in Fig 3. Fig 3. Withdrawal of an Aliquot from XTEMP-R for Partial Dose of TBI-223 Suspension.
195 196 197 198 199	A general technique for withdrawal of aliquots for partial doses is represented in Fig 3. Fig 3. Withdrawal of an Aliquot from XTEMP-R for Partial Dose of TBI-223 Suspension. TBAJ-876 Prior to withdrawal of the dose aliquot, a syringe adapter was attached to the opening of
195 196 197 198 199 200	A general technique for withdrawal of aliquots for partial doses is represented in Fig 3. Fig 3. Withdrawal of an Aliquot from XTEMP-R for Partial Dose of TBI-223 Suspension. TBAJ-876 Prior to withdrawal of the dose aliquot, a syringe adapter was attached to the opening of XTEMP-R and the device was capped. The prepared 25 mL suspension in the XTEMP-R device
195 196 197 198 199 200 201	A general technique for withdrawal of aliquots for partial doses is represented in Fig 3. Fig 3. Withdrawal of an Aliquot from XTEMP-R for Partial Dose of TBI-223 Suspension. TBAJ-876 Prior to withdrawal of the dose aliquot, a syringe adapter was attached to the opening of XTEMP-R and the device was capped. The prepared 25 mL suspension in the XTEMP-R device was shaken 25 times and a 3-mL oral syringe was attached to the syringe adapter. A 2-mL

caregiver. This was repeated on three different preparations. Each 8-mg dose was diluted with
 diluent to a concentration of 0.04 mg/mL, filtered, and analyzed by HPLC. The remaining
 suspension in the XTEMP-R was left undisturbed on the bench for about 24 hours. The
 preparations were redispersed by shaking and one aliquot from each preparation was
 withdrawn and tested.

210 TBI-223

Prior to withdrawal of the dose aliquot, a syringe adapter was fitted on to the device and the 211 device was capped. The prepared 15 mL suspension in the XTEMP-R device was shaken 25 212 213 times and a 3-mL oral syringe was attached to the syringe adapter. A 2-mL aliquot was removed for an 80-mg dose. The dose reproducibility was tested on three 2-mL aliquots withdrawn from 214 215 the same preparation. For each withdrawal of the aliguot, the capped device was shaken to 216 simulate the procedure that would be followed by the patient or caregiver. This was repeated 217 on three different preparations. Each dose withdrawn was transferred into a 100-mL volumetric flask. Acetonitrile 2 mL was added to the flask and swirled to mix the sample with the solvent. 218 The mixture in the flask was then diluted with diluent to volume. An aliquot of 3 mL of this 219 220 stock sample preparation was diluted to 50 mL to a concentration of 0.05 mg/mL. An aliquot of 221 this sample preparation was filtered and analyzed by HPLC. The remaining suspensions in the XTEMP-R were left undisturbed on the bench for about 24 hours and an aliquot from each 222 223 preparation was tested after redispersing.

Analytical test methods for TBAJ-876 and TBI-223

Stability-indicating validated HPLC methods were used for the potency testing of TBI-223 and
 TBAJ-876 suspensions. Details of the HPLC methods are provided in Table 1.

227 Table 1. Details of Stability-Indicating HPLC Methods for Potency Testing of TBI-223 and TBAJ-

228 **876 Suspensions.**

	Details			
Parameter	TBI-223	TBAJ-876		
Instrument	Hitachi L-2100 pump, Shimadzu SPD-10AVP detector, Shimadzu SCL-10AVP controller, Shimadzu CTO-AVP column heater, SRI Instruments PeakSimple chromatography data system			
Column	Zorbax Bonus RP (C18, 4.6 mm x 150 mm, 3.5μm)	Waters Symmetry Shield RP-8 (4.6 mm x 150 mm, 5μm)		
Wavelength	258 nm	236 nm		
Column Temp.	30 °C	40 °C		
Flow Rate	0.8 mL/min	2.0 mL/min		
Injection Volume	10 μL	5 μL		
Syringe filter	1.0 μm glass fiber filter	0.45 μm PVDF syringe filter		
Standard and sample Concentration	0.05 mg/mL	0.04 mg/mL		
Mobile Phase	Mobile Phase-A: 0.05% TFA in water Mobile Phase-B: 0.05% TFA in Acetonitrile	0.01M Ammonium acetate: Acetonitrile (1:3)		
Diluent	0.2% SLS in Water:Acetonitrile (1:1)	Water:Acetonitrile (1:4)		
Run Time	8 minutes (Gradient: 0.0-2.0 mins: A:64% and B:36%; 2.0-4.5 mins: A:64% and B:36% to A:46% and B:54%; 4.6-8.0 mins: A:64% and B:36%)	7 minutes (Isocratic)		
Peak retention time	About 3.6 minutes	About 4.4 minutes		
Integration	Peak area method using PeakSimple data acquisition system	Peak area method using PeakSimple data acquisition system		

229

230 TBAJ-876 quantification method validation

231 The method was validated for specificity (placebo interference and forced degradation),

- linearity, filter study, precision (system suitability and repeatability), and accuracy according to
- 233 International Conference on Harmonization (ICH) guidelines [10]. Specificity was assessed to
- verify the absence of interference from tablet excipients, and suspension matrix and to

- establish the analyte peak does not interfere with the possible degradants of the forced
- 236 degradation of samples. Seven-point calibration curve was constructed with standard solutions
- in the range of 50% (20 μ g/mL) to 150% (60 μ g/mL) of standard concentration i.e., 40 μ g/mL.
- 238 TBI-223 quantification method validation
- 239 The method was validated for specificity (placebo interference and forced degradation),
- linearity, filter study, precision (system suitability and repeatability), and accuracy according to
- 241 ICH guidelines. Specificity was assessed to verify the absence of interference from tablet
- excipients, and suspension matrix and to establish the analyte peak does not interfere with the
- 243 possible degradants of the forced degradation of samples. Five-point calibration curve was
- 244 constructed with standard solutions in the range of 50% (25 μ g/mL) to 150% (75 μ g/mL) of
- standard concentration i.e., 50 μg/mL.

246 Dispersions of commercial tablets prepared in XTEMP-R

247 We tested five different commercially available tablets to determine effectiveness of the

248 XTEMP-R device in producing a fine dispersion that passed through a #18 sieve (1000 um

- opening). The commercial tablets were selected to represent small and large tablets.
- 250 Manufacturer details, composition, tablet weight and drug content of the commercial tablets
- tested are provided in Table 2. Metformin tablets were included for evaluation to challenge the
- dispersing functionality of the XTEMP-R device, as they represent high dose, and high drug load
- tablets with a high drug to excipient ratio.

- 254 We tested the dispersibility of these commercial tablets by using the same methodology of
- soaking them in water for 5 minutes and massaging for 2 minutes, similar to the TBAJ-876 and
- 256 TBI-223 tablets. The suspensions were tested for fineness of dispersion.
- 257 We also tested these commercial tablets for the shortest massaging time that could accomplish
- 258 dispersion for fineness. One tablet was added to the XTEMP-R followed by 5 mL of water and
- 259 massaged in the XTEMP-R device until the analyst felt that the tablet was completely dispersed,
- and the time was recorded. The suspension was poured through a #18 sieve (1000 µm opening)
- with a pan at the bottom for collecting the dispersion. This test was performed in triplicate by
- 262 each of two analysts.

264Table 2. Commercial Tablets Tested for Dispersion Times for Fineness of Dispersion.

Product	Manufacturer	NDC	Inactive Ingredients	Tablet Weight (mg)	% Drug in Tablet
Valsartan 320 mg	MacLeods	33342-065-10	Colloidal silicon dioxide, crospovidone*, hypromellose, iron oxides (yellow, black and/or red), microcrystalline cellulose, magnesium stearate, polyethylene glycol, talc and titanium dioxide	1030	31.1
Acetaminophen 500 mg (Tylenol®)	McNeil	50580-449-96	Carnauba wax, corn starch, FD&C red no. 40 aluminum lake, hypromellose, magnesium stearate, modified starch, polyethylene glycol, powdered cellulose, pregelatinized starch, propylene glycol, shellac, sodium starch glycolate*, titanium dioxide	610	82.0
Glimepiride 2 mg	Accord	16729-002-01	Lactose monohydrate, sodium starch glycolate*, povidone, and magnesium stearate. Ferric oxide yellow and FD &C blue #2 aluminum lake	170	1.2
Amlodipine 2.5 mg	Ascend	67877-197-90	Microcrystalline cellulose, dibasic calcium phosphate anhydrous, sodium starch glycolate*, colloidal silicon dioxide and magnesium stearate	100	2.5
Metformin 1000 mg	Ascend	67877-563-01	Povidone (K-30), povidone (K-90), pregelatinized starch*, and magnesium stearate. Coating: artificial blackberry flavor, hypromellose and polyethylene glycol.	1080	92.6

265 *disintegrant

263

266 **Results**

267 Preparation of suspensions from tablets using XTEMP-R

268 **TBAJ-876 and TBI-223**

- 269 The suspension preparation technique for the two tablets, TBAJ-876 and TBI-223, was found to
- 270 be simple, efficient and could be performed well in this closed system. The suspensions were
- 271 prepared in less than 10 minutes without any complicated, tedious, or messy steps. The details
- of the suspension evaluation are provided below.

273 Evaluation of suspensions prepared in XTEMP-R

274 Visual observation

275 TBAJ-876 and TBI-223

- Fig 4 shows the visual appearance of the suspensions of the two drugs, TBI-223 and TBAJ-876.
- 277 Both suspensions had uniform appearance and the particles were observed to be
- 278 homogeneously dispersed. TBI-223 suspension was observed to be milky white, opaque, and
- 279 uniform when light was shown from below the watch glass containing the suspension. TBAJ-876
- suspension was translucent with distinct particles visible and uniformly dispersed. The
- 281 appearance of the suspension as translucent or opaque is dependent on the ingredients and
- composition of the tablets and the dispersion vehicle.

Fig 4. Visual Observation of Suspensions Prepared in XTEMP-R. (a) Appearance of TBAJ-876
 suspension, (b) TBAJ-876 suspension in XTEMP-R device, (c) Appearance of TBI-223 suspension,
 (d) TBI-223 suspension in XTEMP-R device.

- 286
- 287 Fineness of dispersion
- 288 TBAJ-876 and TBI-223

- 289 The dispersions prepared with 5-minute soaking and 2-minute massaging times in the XTEMP-R
- 290 device passed through the #18 sieve. No particles were retained indicating that all particles
- were below 1000 μ m and dispersed particles were not forming aggregates or agglomerates.

292 Total dose recovery from tablet dispersion in XTEMP-R

293 TBAJ-876 and TBI-223

- 294 The total dose recovered from the triplicate preparations of TBAJ-876 and TBI-223 in XTEMP-R
- are presented in Table 3. The recovery of TBAJ-876 from three distinct preparations in XTEMP-R
- ranged from 98.8-100.0% with an average recovery of 99.2%. The recovery of TBI-223 from
- 297 three distinct preparations in XTEMP-R ranged from 100.4-102.9% with an average recovery of
- 298 101.3%. These ranges include inherent tablet-to-tablet content variability as well as analytical
- 299 variability.
- 300

301 Table 3. Recovery of TBI-223 and TBAJ-876 from Suspensions Prepared in XTEMP-R.

Tablet	Suspending Agent	Dispersion time (minutes)	Preparation	Total Recovered (%) from entire contents in device
			1	98.8
	Water + ORA-	5 minutes soak+2	2	100.0
TBAJ-876	Sweet	minutes massage	3	99.0
			Average (RSD)	99.2 (0.64)
			1	100.4
TDI 222	Water + ORA-	5 minutes soak+2	2	100.5
TBI-223	Blend	minutes massage	3	102.9
			Average (RSD)	101.3 (1.4)

302 RSD = relative standard deviation

Dose reproducibility of aliquots of tablet dispersion in XTEMP-R

304 TBAJ-876 and TBI-223

- 305 The results for dose reproducibility are provided in Table 4. Average potency of three
- 306 suspensions from three replicate aliquots of 2-mL from each suspension were found to be
- 307 98.9-99.7% for TBI-223 suspensions, and 102.6-103.2% for TBAJ-876 suspensions. The potency
- 308 of an additional aliquot withdrawn after redispersing after 24 hours from each of the three
- suspensions was found to be 96.0-100.3% for TBAJ-876 suspensions and 99.3-100.3% for
- 310 TBI-223 suspensions.

Table 4. Dose Reproducibility of Aliquots Withdrawn from TBAJ-876 and TBI-223 Suspensions.

Tablet	Suspending Agent		Theoretical dose dispensed (%)		
		Aliquot	Preparation 1	Preparation 2	Preparation 3
TBAJ-876	Water + ORA-Sweet	Day 0	99.2	101.2	102.2
			104.5	102.5	104.3
			105.7	104.2	103.0
		Average (RSD)	103.1 (3.44)	102.6 (1.44)	103.2 (0.99)
		Day 1	96.0	100.3	98.2
TBI-223	Water + ORA-Blend	Day 0	99.4	98.8	99.9
			98.5	98.9	99.8
			99.3	98.9	99.5
		Average (RSD)	99.1 (0.5)	98.9 (0.1)	99.7 (0.2)
		Day 1	100.3	99.3	100.2

313 RSD = relative standard deviation

314 TBAJ-876 tablets test method validation

- The seven-point calibration curve in the range of 20 μ g/mL to 60 μ g/mL was linear with a high
- 316 correlation coefficient (r) of 1.000. For both standard and sample tests, % RSD for inter- and
- intra-day precision were well below 2%, and mean recovery was well within the range of 98% to
- 318 102%.

319 TBI-223 tablets test method validation

- 320 The five-point calibration curve in the range of 25 μ g/mL to 75 μ g/mL was linear with a high
- 321 correlation coefficient (r) of 1.000. For both standard and sample tests, % RSD for precision
- were well below 2%, and mean recovery was well within the range of 98% to 102%.

323 Dispersions of commercial tablets prepared in XTEMP-R

- 324 The suspensions prepared with 5-minute soaking and 2-minute massaging times in the
- 325 XTEMP-R device passed through the #18 sieve. No particles were retained indicating that all
- particles were below 1000 μm and dispersed particles were not forming aggregates or
- 327 agglomerates.

328 The earliest dispersion times for all commercial tablets tested ranged from 1-3 minutes except

- for metformin which did not disintegrate within the time tested (10 minutes soaking and 5
- 330 minutes massaging). The dispersion times presented in Table 5 represent the dispersion time
- 331 for the suspensions prepared by two independent analysts that passed the fineness of

dispersion test.

333 The drug content (labelled dose of the drug in total tablet weight) and disintegrant in each

tablet formulation are provided in Table 2. Except for metformin, all other tablet formulations

- 335 contained superdisintegrants. Valsartan, acetaminophen, and metformin had 31, 82, and 93%
- of drug load, respectively. Glimepiride and amlodipine contained 1.2 and 2.5% of drug load,
- 337 respectively.

338 **Table 5. Dispersion Times of Commercial Tablets.**

Tablet	Dispersion Time (min) in X-TEMP-R
Valsartan	1.5
Acetaminophen	3
Glimepiride	3
Amlodipine	1
Metformin	>10*

^{*}Did not disperse in time tested (10 minutes soaking and 5-minute massaging)

340 **Discussion**

Tablet splitting, crushing, and grinding is a common practice for medication administration. The

necessity for splitting or crushing tablets arises from the need to administer drug doses other

than that are available in tablet formulations, as well as facilitate the swallowing of tablets [11].

344 There have been some challenges identified with both, tablet splitting and tablet pulverization.

- Large deviations of dose can occur due to unequal fragments of split tablets or weight
- differences due to loss of powdered or chipped material resulting from the splitting process [9].
- 347 Tablet crushing can result in significant drug loss [5]. Some crushing devices yield large particles
- that cannot be administered via a feeding tube [4]. Aerosolized powder during crushing and

349 grinding can be an environmental [2] and health hazard.

350 This paper describes a procedure for converting tablets into a suspension: (1) that is simple and

reproducible; (2) where tablet disintegration and preparation of suspension is performed within

the same device; (3) in a contained environment; (4) that enables measurement and
withdrawal of any required dose with accuracy; (5) with small particle size that permits
administration through feeding tubes; and (6) where consumption is possible from the same
receptacle.

356 XTEMP-R is a simple mechanical device designed to facilitate and expedite the disintegration 357 and dispersion of tablets in a small volume (<10 mL) of water. This device is constructed with 358 low hardness silicone, making it pliable yet durable. It can be gently squeezed by fingers to 359 facilitate the dispersion of the tablet. This squeezing and massaging action facilitated the 360 interaction of water with the superdisintegrants present in the tablet, thus promoting its 361 dispersion. These ingredients are routinely included in the tablet formulations to aid in the 362 break-up of the compacted mass.

The disintegration and suspension of tablets in the XTEMP-R device occurs in the same container in a closed environment. Therefore, there is minimal risk of any drug loss during the preparation. The XTEMP-R container does not have any cutting or grinding parts. It is also safer for caregivers to prepare the suspension with XTEMP-R since there is minimal contact with the drug either by touch or by inhalation of drug powder that may get aerosolized during pulverization.

Both TBAJ-876 and TBI-223 tablets are investigational drugs under IND applications with
established specifications and content uniformity standards. As demonstrated by the results,
TBAJ-876 and TBI-223 tablets could be dispersed homogenously in water and suspending
vehicle within 10 minutes. Accurate aliguots could be withdrawn reproducibly from the device

immediately after the preparation and 24 hours later. We withdrew aliguots from each 373 374 preparation sequentially after preparation and on the following day after redispersing by shaking. This closely simulates what would occur in the pharmacy, at the patient's home or at 375 376 the clinical investigation site. The partial doses withdrawn for the suspension were uniform and 377 stable as they could be redispersed reproducibly after 24 hours. It was not our intent to 378 prepare suspensions for long term storage. Fineness of dispersion was one of the quality criteria. The suspensions were tested by passing 379 380 them through a #18 sieve (1000 μ m aperture). Our objective was to ensure that no particle 381 agglomerates were present in the suspension and that the largest particles in the suspension 382 could be suspended in commonly available suspending vehicles. Bowles and colleagues [13]

 $_{383}$ have demonstrated that particles up to 1000 μm can be successfully suspended with the aid of

384 commonly used suspending vehicles.

Drug loss is one of the challenges when the tablets are pulverized before dispersing in a 385 suspension. Drug powder tend to stick to the walls of the container such as a mortar and pestle. 386 Thong and colleagues [5] have recommended two rinses of the tablet crushing devices to 387 ensure minimum drug loss. Close to 100% of active drug from all three suspensions of TBAJ-876 388 and TBI-223 prepared by the XTEMP-R device was recovered. The devices were only rinsed once 389 with 15 mL of water for each preparation. The total dose could be ingested directly from the 390 device avoiding a transfer to a dispensing container. This methodology offers an alternative 391 392 dose administration option for patients suffering from dysphagia.

We have also investigated the applicability of this device for some commercial tablets. Except 393 394 for metformin, the tablets could be dispersed by soaking for 5 minutes and massaging for 2 minutes. For some products, the dispersion could be faster by just massaging for 1-3 minutes. 395 The metformin tablets had a high drug load with just about 8% excipients and did not contain 396 397 any superdisintegrants. Desai and colleagues [14] studied metformin formulation with minimal excipients and concluded that even for a highly soluble drug, a superdisintegrant was needed in 398 the formulation to change the dissolution mechanism from erosion-diffusion to disintegration. 399 400 Masum and colleagues [15] formulated metformin tablets with different disintegrants and 401 found that the wetting time, dispersion time and the disintegration time of metformin tablets were governed by the type and quantity of the superdisintegrants. In the XTEMP-R device, the 402 403 volume of the dispersing vehicle (5-7 mL water) and massaging are not sufficient to have effective erosion-diffusion for the tablet to dissolve or disperse the metformin tablet. 404 405 Therefore, the use of the XTEMP-R device may be limited for tablets that depend primarily on solubilization for dissolution and do not contain effective disintegrants. These observations 406 corroborate our assumption that XTEMP-R promotes the interaction between water and tablet 407 formulations. The ingredients of each tablet formulation can be found in the product 408 prescribing information. 409

The lack of child-friendly formulations leaves 40% of the world population at increased risk for preventable adverse events, suboptimal dosing, noncompliance, and lack of access to new medicines [16]. In some instances, the caregiver is required to administer a quarter of a tablet to a neonate. XTEMP-R device may offer an alternative for accurate dosing in this patient population. Of course, appropriate development and analytical work will have to be performed.

- Fortunately, several publications [17,18] describing the compatibility of drugs that lack pediatric
- 416 formulations with commonly available suspending agents and with established storage
- 417 conditions and shelf life are available.

418 Limitations

- 419 XTEMP-R device worked well with the tablets containing superdisintegrants in the formulation.
- 420 This device, however, may not work well with certain large tablets with a high drug-to-excipient
- ratio and/or tablets not containing effective disintegrants in the formulation. This will have to
- 422 be tested on a case-by-case basis.
- 423 This device does not offer protection from light. Photosensitive drug preparations should be
- 424 stored in the device with added protection from light.
- 425 The silicone material of the XTEMP-R device may be stained from a colored drug dispersion.
- 426 Therefore, it is recommended that a dedicated device should be used for colored drugs such as

427 clofazimine.

- 428 Dose preparation may be challenging for patients that are unable to massage the tablet in the
- 429 device. XTEMP-E[™], another version of XTEMP-R is equipped with an electronic mechanism for
- 430 mixing. XTEMP-E will be presented in a subsequent publication.
- 431 The utility of this device and methodology for suspending any tablet formulation has to be
- 432 supported by appropriate development and analytical work. As exemplified by the work
- 433 conducted for TBAJ-876 and TBI-223 in this paper, similar rigor is recommended for any other
- 434 drug that will utilize XTEMP-R for suspension.

435 **Conclusion**

- 436 We have demonstrated that the new XTEMP-R device can be utilized for aliquoting partial
- 437 doses of TBAJ-876 and TBI-223 immediate release tablets. Homogeneous suspensions could be
- 438 prepared conveniently, safely, and expeditiously without any significant loss. Further, this
- 439 device has the potential to offer an alternative for dosing patients who cannot ingest
- immediate release tablets. This could be beneficial to pediatric and elderly patients, intubated
- 441 patients, and patients with dysphagia. Additional work is required to establish the utility of the
- 442 device for other immediate release tablets.

443 Acknowledgements

The authors are grateful for the funding provided by TB Alliance.

445 **References**

446	1.	Ranked: The most prescribed drugs in the U.S. by Omri Wallach, Graphics/Design:
447		Amy Realey; 2021 Nov 1; https://www.visualcapitalist.com/ranked-the-most-
448		prescribed-drugs-in-the-u-s/. (accessed 2021 Dec 12).
449	2.	Damien Salmon, Elisa Pont, Hélène Chevallard, Elhadji Diouf, Mamadou-Lamine Tall,
450		Christine Pivot, Fabrice Pirot, Pharmaceutical and safety considerations of tablet
451		crushing in patients undergoing enteral intubation, International Journal of
452		Pharmaceutics, Volume 443, Issues 1–2, 2013, Pages 146-153, ISSN 0378-5173,
453		https://doi.org/10.1016/j.ijpharm.2012.12.038.
454	3.	Diana A. van Riet Nales, Piotr Kozarewicz, Siri Wang, Agnes Saint-Raymond, Jean-
455		Louis Robert, Comments on the EMA draft guideline: Final steps towards a
456		harmonized view between regulators and industry, International Journal of
457		Pharmaceutics, Volume 457, Issue 1, 2013, Pages 337-339, ISSN 0378-5173,
458		<u>https://doi.org/10.1016/j.ijpharm.2013.08.060</u> .
459	4.	Woerdenbag HJ, Visser JC, Leferink Op Reinink MPAM, van Orsoy RR, Eissens AC,
460		Hagedoorn P, Dijkstra H, Allersma DP, Ng SW, Smeets OSNM, Frijlink HW.
461		Performance of Tablet Splitters, Crushers, and Grinders in Relation to Personalised
462		Medication with Tablets. Pharmaceutics. 2022 Jan 28;14(2):320. doi:
463		10.3390/pharmaceutics14020320. PMID: 35214052; PMCID: PMC8878961.
464	5.	Thong MY, Manrique YJ, Steadman KJ (2018) Drug loss while crushing tablets:
465		Comparison of 24 tablet crushing devices. PLOS ONE 13(3): e0193683.

100		https://doi.ovg/10.1271/journal.page.0102022. DNALD: 20404005. DNACID:
466		https://doi.org/10.1371/journal.pone.0193683; PMID: 29494695; PMCID: PMC5832315.
467 468	6.	Helmy SA. Tablet splitting: is it worthwhile? Analysis of drug content and weight
408 469	0.	uniformity for half tablets of 16 commonly used medications in the outpatient
409		setting. J Manag Care Spec Pharm. 2015 Jan;21(1):76-86. doi:
470		10.18553/jmcp.2015.21.1.76. PMID: 25562775.
471	7.	Starling, Flavio & Camargos, Einstein & Ferreira, Felipe & Polo, Marco & Freitas,
473	7.	Marco Polo & Costa, Reinaldo & Medeiros-Souza, Patricia. (2019). UNAVAILABILITY
474		OF APPROPRIATE DOSES AND NEED FOR TABLET SPLITTING OF PSYCHOTROPIC
475		DRUGS BY GERIATRIC PATIENTS Indisponibilidade de doses apropriadas e
476		necessidade de fracionamento de medicamentos psicotrópicos por pacientes
477		geriátricos. Geriatr Gerontol Aging. 2019;13(3):126-32.
478	8.	Freeman MK, White W, Iranikhah M. Tablet splitting: a review of weight and content
479		uniformity. Consult Pharm. 2012 May;27(5):341-52. doi: 10.4140/TCP.n.2012.341.
480		PMID: 22591978.
481	9.	Verrue C, Mehuys E, Boussery K, Remon JP, Petrovic M. Tablet-splitting: a common
482		yet not so innocent practice. J Adv Nurs. 2011 Jan;67(1):26-32. doi: 10.1111/j.1365-
483		2648.2010.05477.x. PMID: 21158902.
484	10.	International Conference on Harmonisation of Technical Requirements for
485		Registration of Pharmaceuticals for Human Use (ICH). Guidance for Industry, Q2B
486		Validation of Analytical Procedures: Methodology. 1996, ICH-Quality final guidance
487		FDA issue date 1997. <u>https://www.fda.gov/regulatory-information/search-fda-</u>
488		guidance-documents/q2b-validation-analytical-procedures-methodology
489	11.	Pahwa, R, Gupta, N. Superdisintegrants in the development of orally disintegrating
490		tablets: a review. Int J Pharm Sci Res 2010; 2: 2767-80.
491		http://dx.doi.org/10.13040/IJPSR.0975-8232.2(11).2767-80
492	12.	Markl D, Zeitler JA. A Review of Disintegration Mechanisms and Measurement
493		Techniques. Pharm Res. 2017 May;34(5):890-917. doi: 10.1007/s11095-017-2129-z.
494	_	Epub 2017 Mar 1. PMID: 28251425; PMCID: PMC5382187.
495	13.	Bowles, A., Ernest, T., Clapham, D., & Tuleu, C. (2010, November). Evaluation of the
496		rheological and suspending properties of commonly used oral suspending vehicles.
497		Poster presented at International Pharmaceutical Federation World
498		Congress/Annual Meeting American Association of Pharmaceutical Scientists, New
499		Orleans, USA
500	14.	Desai D, Wong B, Huang Y, Tang D, Hemenway J, Paruchuri S, Guo H, Hsieh D,
501		Timmins P. Influence of dissolution media pH and USP1 basket speed on erosion and
502		disintegration characteristics of immediate release metformin hydrochloride tablets.
503		Pharm Dev Technol. 2015;20(5):540-5. doi: 10.3109/10837450.2014.892132. Epub
504 505	15.	2014 Mar 12. PMID: 24621340. Masum MA et al., Effect of Superdisintegrants on Physical Attribute and Release
505 506	13.	Profile of Metformin HCl Immediate Release Tablets. American Journal of
506 507		PharmTech Research 2013; 3(1):1025-1036. ISSN:2249-3387
307		r nanni eun Nesearun 2013, 3(1).1023-1030. 13311.2243-3307

- 508 16. Milne CP, Bruss JB. The economics of pediatric formulation development for off-
- 509 patent drugs. Clin Ther. 2008 Nov;30(11):2133-45. doi:
- 510 10.1016/j.clinthera.2008.11.019. PMID: 19108801.
- 511 17. Jew RK, Soo-Hoo W, Erush SC, *et al.* Extemporaneous formulations for pediatric, 512 geriatric, and special needs patients, 3rd ed. ASHP, 2016.
- 51318.Nahata, MC, Pai, VB. Pediatric drug formulations, 7th ed. Harvey Whitney Books514Company, 2018.


516 Supporting Information


- 517 Link to video for suspension preparation methodology
- 518 https://www.dropbox.com/sh/t0bj2o6ivjuh8l3/AAAZe3mRxc1HImGlbpoFDUUua?dl=0
- 519 S1 Fig. Representative chromatograms of TBAJ-876 analysis (a) Standard 1, (b) Diluent blank,
- 520 (c) Day 0 aliquot for dose reproducibility, (d) Day 0 suspension matrix blank (diluent + ORA-
- 521 Sweet), (e) Day 1 aliquot for dose reproducibility, (f) Day 1 suspension matrix blank (diluent +
- 522 ORA-Sweet), (g) Standard 2, (h) Total dose recovery
- 523 S2 Fig. Representative chromatograms of TBI-223 analysis (a) Standard 1, (b) Diluent blank, (c)
- 524 Day 0 aliquot for dose reproducibility, (d) Day 0 suspension matrix blank (diluent + ORA-Blend),
- 525 (e) Day 1 aliquot for dose reproducibility, (f) Day 1 suspension matrix blank (diluent + ORA-
- 526 Blend), (g) Standard 2, (h) Total dose recovery

527

Author contributions

Rajneesh Taneja conceptualized and designed the device and experiments Joseph Scarim conceptualized and designed the device and experiments Poonam G Pande designed and coordinated the testing, corresponding author Anthony Scarim conducted the analytical work Milap C Nahata consulted on the utility of the device Rita K Jew consulted on the utility of the device Koteswara Inabathina coordinated the device manufacture






























(c)